Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NYSE:HIMS NYSE:PACS NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$88.95-2.7%$122.64$11.27▼$151.02$4.46B0.11.26 million shs5.48 million shsHIMSHims & Hers Health$27.49-0.1%$24.37$13.74▼$70.43$6.37B2.3722.71 million shs13.70 million shsPACSPACS Group$36.49-1.1%$35.04$7.50▼$43.08$5.84BN/A955,789 shs576,053 shsVRDNViridian Therapeutics$16.35+3.0%$17.08$13.18▼$34.29$1.64B0.92.76 million shs1.69 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity-2.70%-33.60%-29.21%-22.81%+644.97%HIMSHims & Hers Health-0.07%+8.93%+0.47%+73.34%-49.82%PACSPACS Group-0.91%-7.24%+10.50%+2.66%+258.42%VRDNViridian Therapeutics+3.02%-5.27%+21.83%-43.41%+13.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$88.95-2.7%$122.64$11.27▼$151.02$4.46B0.11.26 million shs5.48 million shsHIMSHims & Hers Health$27.49-0.1%$24.37$13.74▼$70.43$6.37B2.3722.71 million shs13.70 million shsPACSPACS Group$36.49-1.1%$35.04$7.50▼$43.08$5.84BN/A955,789 shs576,053 shsVRDNViridian Therapeutics$16.35+3.0%$17.08$13.18▼$34.29$1.64B0.92.76 million shs1.69 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity-2.70%-33.60%-29.21%-22.81%+644.97%HIMSHims & Hers Health-0.07%+8.93%+0.47%+73.34%-49.82%PACSPACS Group-0.91%-7.24%+10.50%+2.66%+258.42%VRDNViridian Therapeutics+3.02%-5.27%+21.83%-43.41%+13.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$152.0970.98% UpsideHIMSHims & Hers Health 2.12Hold$28.704.40% UpsidePACSPACS Group 2.71Moderate Buy$48.0031.55% UpsideVRDNViridian Therapeutics 2.79Moderate Buy$36.14121.06% UpsideCurrent Analyst Ratings BreakdownLatest VRDN, CELC, HIMS, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CELCCelcuity Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$189.00 ➝ $171.006/3/2026CELCCelcuity GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$183.00 ➝ $166.006/3/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$185.00 ➝ $145.006/2/2026CELCCelcuity Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$155.005/28/2026CELCCelcuity Macquarie InfrastructureSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$160.005/28/2026CELCCelcuity CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/22/2026HIMSHims & Hers Health Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$18.00 ➝ $23.005/19/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$2.17 per shareN/AHIMSHims & Hers Health$2.35B2.71$0.84 per share32.87$2.38 per share11.55PACSPACS Group$5.29B1.09$1.58 per share23.09$6.08 per share6.00VRDNViridian Therapeutics$70.85M23.79N/AN/A$6.18 per share2.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A2,223.75N/AN/A-244.61%-50.22%8/13/2026 (Estimated)HIMSHims & Hers Health$128.37M-$0.09N/A56.1053.38-0.56%6.10%1.52%8/10/2026 (Estimated)PACSPACS Group$191.54M$1.5623.3914.951.124.49%26.47%4.36%8/10/2026 (Estimated)VRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%8/5/2026 (Estimated)Latest VRDN, CELC, HIMS, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/11/2026Q1 2026PACSPACS Group$0.42$0.50+$0.08$0.50$1.36 billion$1.42 billion5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 million3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31HIMSHims & Hers Health2.181.691.56PACSPACS Group0.270.990.99VRDNViridian Therapeutics0.1015.1515.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%HIMSHims & Hers Health63.52%PACSPACS GroupN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%HIMSHims & Hers Health11.76%PACSPACS Group70.10%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionablePACSPACS Group47,455158.27 million47.32 millionOptionableVRDNViridian Therapeutics50103.07 million100.60 millionOptionableVRDN, CELC, HIMS, and PACS HeadlinesRecent News About These CompaniesViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 3 at 6:14 AM | americanbankingnews.comViridian Therapeutics Fully Repays Loan, Ends AgreementMay 28, 2026 | tipranks.comViridian Therapeutics secures WuXi deal for veligrotug manufacturingMay 26, 2026 | tipranks.comViridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350MMay 21, 2026 | finance.yahoo.comViridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel ProjectMay 19, 2026 | globenewswire.comViridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberMay 17, 2026 | businesswire.comThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMay 17, 2026 | fool.comViridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special MeetingMay 14, 2026 | globenewswire.comInsider Buying: Viridian Therapeutics (NASDAQ:VRDN) Director Acquires 1,176,470 Shares of StockMay 14, 2026 | insidertrades.comViridian Therapeutics Raises $359 Million in OfferingsMay 13, 2026 | theglobeandmail.comVanguard Group Inc. Raises Holdings in Viridian Therapeutics, Inc. $VRDNMay 11, 2026 | marketbeat.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - SlideshowMay 9, 2026 | seekingalpha.comViridian Therapeutics (NASDAQ:VRDN) Upgraded at Wall Street ZenMay 9, 2026 | marketbeat.comEarnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their EstimatesMay 8, 2026 | finance.yahoo.comWhy Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh FundraisingMay 8, 2026 | finance.yahoo.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase - Time to Buy?May 7, 2026 | marketbeat.comViridian (VRDN) Climbs 33% on Looming Drug CommercializationMay 7, 2026 | finance.yahoo.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350 ...May 7, 2026 | finance.yahoo.comViridian Therapeutics prices upsized $350M concurrent stock and convertible notes offeringsMay 7, 2026 | msn.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionMay 6, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026VRDN, CELC, HIMS, and PACS Company DescriptionsCelcuity NASDAQ:CELC$88.95 -2.47 (-2.70%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$87.63 -1.32 (-1.48%) As of 06/3/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Hims & Hers Health NYSE:HIMS$27.49 -0.02 (-0.07%) Closing price 06/3/2026 03:58 PM EasternExtended Trading$26.80 -0.69 (-2.51%) As of 06/3/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.PACS Group NYSE:PACS$36.49 -0.42 (-1.15%) Closing price 06/3/2026 03:58 PM EasternExtended Trading$36.50 +0.01 (+0.04%) As of 06/3/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Viridian Therapeutics NASDAQ:VRDN$16.35 +0.48 (+3.02%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$16.48 +0.13 (+0.79%) As of 06/3/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
